Please assess the completion status of the following clinical trial:

Trial Title: YF476 and Type II Gastric Carcinoids

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion criteria:~1. Men; post-menopausal women; pre-menopausal women who have been sterilised by tubal ligation, hysterectomy or bilateral oophorectomy; or pre-menopausal women using one of the allowed methods of contraception: condom and spermicide or intra-uterine device.~2. Patients with serum gastrin \>250 pg/mL.~3. Hepatic function: AST and ALT ≤2.0 x ULN; total bilirubin ≤1.0 x ULN.~4. Renal function: serum creatinine \<1.0 x ULN.~5. Haematologic function: Hb ≥10.0 g/dL; WBC ≥3.5 x 10e9 /L; ANC ≥1.5 x 10e9 /L; platelets ≥100 x 10e9 /L.~6. Coagulation parameters: INR or PT ≤1.0 x ULN; PTT ≤1.0 x ULN.~7. Ability to communicate satisfactorily with the investigator and to participate in, and comply with the requirements of, the entire trial.~8. Willingness to give fully-informed, written consent.~Exclusion criteria:~1. Patients under 18 years.~2. Women who are pregnant, lactating or using a steroid contraceptive.~3. Prior gastric resection or bypass.~4. Planned gastrinoma resection during the study period.~5. Patients on somatostatin analogues, except for those on therapy for \>6 months with stable or worsening carcinoids.~6. Inability to tolerate endoscopy, or refusal of endoscopy.~7. Physical findings, ECG (especially prolonged QTc interval \>450 msec), or laboratory values at the pre-trial screening assessment that could interfere with the objectives of the trial or the safety of the subject.~8. Certain medicines and herbal remedies taken during the 7 days before visit 2.~9. Participation in a trial of an IMP within the previous 28 days.~10. Presence of drug or alcohol abuse.~11. History or baseline findings of:~    * type 1 diabetes mellitus;~   * pancreatitis (baseline amylase and/or \>2.0 x ULN);~   * hepatitis B, hepatitis C or HIV;~   * malabsorption syndrome or inability to swallow or retain oral medicine;~   * major surgery \<28 days prior to enrolment;~   * ECOG performance status \>2; or~   * another cancer within 3 years except for basal carcinoma of the skin or cervical carcinoma in-situ.~   * Also, any clinically significant and uncontrolled major morbidity including but not limited to; serious cardiac disease (unstable angina, s/p myocardial infarction \<1 month); respiratory disease (advanced COPD or pulmonary fibrosis); uncontrolled hypertension; or active systemic infection.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Eligible patients (Type: EXPERIMENTAL): The dose will be 100 mg YF476 once daily. When 6 patients have completed 12 weeks' treatment with that dose, it may be increased to 150 or 200 mg once daily. Patients will have type II gastric carcinoids and/or ECL cell hyperplasia/dysplasia.

Based on this trial design, predict the completion outcome and termination type (if applicable).